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Diabetic nephropathy is the most common cause of end-stage renal failure in the western 
world and Asia. The mechanisms are not fully elucidated, but disruption of glomerular 




We hypothesize that reduced glomerular filtration in diabetes is caused by disruption of 
endothelial glycocalyx in glomeruli, including increased shedding of syndecan-4. The aim of 
this study was to determine the effects of experimental diabetic conditions by means of 
hyperglycemia and IL-1β exposure on syndecan-4 shedding in glomerular endothelial cells 
(GEnC), and to investigate regulation of shedding by sheddases.  
 
Results: 
We found that in GEnC the expression of syndecan-4 is higher than that of the other 
syndecans. In polarized GEnC, apical shedding of syndecan-4 and syndecan-4 gene 
expression was increased by 60% after IL-1β stimulation, but not affected by hyperglycemic 
conditions. This was accompanied by a 50% increase in MMP9 gene expression in IL-1β 







IL-1β but not hyperglycemia increases the shedding of syndecan-4 from GEnC in an MMP9-
dependent manner. This provides a potential mechanism of GEnC damage in diabetes and 
other inflammatory conditions. 
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All healthy vasculature is covered by an endothelial glycocalyx. This is a hydrated polyanionic 
gel consisting of cell-surface anchored proteoglycans including syndecans, as well as 
glycoproteins and glycolipids, supplemented with adsorbed soluble proteoglycans, 
glycosaminoglycans and plasma constituents (1). In the glomeruli, the basement membrane, 
podocytes and glomerular endothelium with its glycocalyx are all part of the filtration barrier 
(2). During pathological conditions components of the glycocalyx are shed, decreasing the 
size of the glycocalyx, increasing the endothelial permeability and reducing filtration capacity 
of the glomeruli, ultimately resulting in proteinuria (3). These components are released into 
the blood and can be detected in human serum.  
Diabetes mellitus (DM) is a state of both chronic and acute hyperglycemia, and low-grade 
inflammation (4, 5), and It is known that short-term hyperglycemia induces insulin resistance, 
endothelial dysfunction and increase the vascular permeability (6-8) Diabetic nephropathy is 
the most common cause of end-stage renal failure in the western world and Asia (9, 10). The 
mechanisms behind the impaired filtration capacity of the kidneys are not fully elucidated, 
although hyperglycemia is recognized as an important risk factor for the development of 
diabetic nephropathy. Glucose-induced increased levels of interleukin 1β (IL-1β) in the 
circulation are seen both in Type 1 (T1)DM and T2DM (11, 12). IL-1β levels could reflect 
severity of the disease, and in a recent study we measured higher levels of IL-1β together 
with higher glycated hemoglobin A1c (HbA1c) in patients with T1DM and kidney failure 




The syndecans are a group of four transmembrane proteoglycans that are part of the 
endothelial glycocalyx and constituents of focal adhesion sites facing the basement 
membrane as well as components of the basement membrane itself (14, 15). Syndecan-1 
and -3 are substituted with both heparan sulfate and chondroitin sulfate chains, while 
syndecan-2 and -4 are decorated with heparan sulfate chains only. The functionality of the 
syndecans is contributed by these glycosaminoglycans through their interaction with 
different extracellular ligands. Such ligands include anticoagulants such as antithrombin and 
growth factors like fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) 
and transforming growth factor-β (TGFβ), in addition to different proteases, protease 
inhibitors and cytokines. In line with this, we have previously demonstrated a major role for 
syndecan-4 in angiogenesis (16).  
 
All syndecans can be shed from the cell surface of endothelial cells by the action of 
sheddases (17), resulting in increased syndecan serum levels. Soluble syndecan ectodomains 
can function as paracrine and autocrine effectors or competitors, and may have important 
functions in influencing coagulation pathways, angiogenesis or inflammation. Syndecan 
shedding is increased as a response to acute vascular trauma, as we have demonstrated for 
syndecan-1 (18). We have also documented that increased serum syndecan-1 is related to 
early diabetic nephropathy (19), and we observed a trend for increased syndecan-1 serum 
levels in the hyperglycemic group compared to normoglycemic kidney transplanted patients 
together with increased levels of the syndecan-1 sheddase matrix metalloproteinase-9 
(MMP-9) (20). This promising potential for syndecans as markers for endothelial dysfunction 
is further strengthened by our most recent results generated. In a case-cohort study 




an independent predictor of myocardial infarction and correlated with baseline estimated 
glomerular filtration rate (eGFR) (21). 
 
The different syndecans have different cell- and tissue- specific expressions and functions. It 
is commonly reported that syndecan-3 is mainly expressed in neural cells, while syndecan-4 
is high in epithelium and fibroblasts, and low in neural and endothelial cells (22) (23). In 
contrast to this, we have published data demonstrating high expression of both syndecan-4 
and syndecan-3 in human umbilical vein endothelial cells (HUVEC) but low expression of 
syndecan-1 and -2 (16). The high endothelial expression of syndecan-3 and -4 is also 
supported by other recent publications (24-26). Conditionally immortalized glomerular 
endothelial cells (ciGEnC) are the cells of choice to study endothelial glycocalyx in glomeruli. 
These cells are covered by an extensive glycocalyx of up to 200 nm (2), and also express 
several cell surface proteoglycans including syndecan-4 (27), likely to contribute to the 
integrity of the glomerular filtration barrier.  
We hypothesize that impaired regulation of glomerular filtration in diabetes is caused by 
disruption of the endothelial glycocalyx in the glomeruli, including increased shedding of 
syndecan-4. The aim of this study was to determine the effects of experimental diabetic 
conditions on syndecan-4 shedding in glomerular endothelial cells, and to investigate how 






Materials & Methods 
ciGEnC culture 
The human ciGEnC have previously been characterized in detail (2, 28). In short, primary 
culture GEnC were transduced with temperature-sensitive (ts) simian virus 40 large tumor 
(SV40LT) antigen and telomerase using retroviral vectors. At the permissive temperature 
(33oC) the tsSV40LT transgene is activated causing cell proliferation without telomere 
shortening. At 37 oC the transgene is inactivated and the cells retain their properties as 
primary cells. Cells were cultured in MCDB 131 medium (Sigma) containing 5 mM glucose 
and supplemented with 7% heat-inactivated FCS (Sigma), basicFGF (1 ng/ml, R&D), 
hydrocortisone (1 μg/ml, Sigma), EGF (10 ng/ml, R&D), gentamicine (50 μg/ml, GIBCO 
Invitrogen) and fungizone (250 ng/ml, GIBCO Invitrogen) at 5% CO2. The cells were 
subcultured at the permissive temperature and used for experiments after 5 days at 37  oC. 
Incubations with IL-1β (R&D systems) were performed for 24 hours using a concentration of 
0.5 ng/ml; determined by dose-response and time-response experiments (not shown). 
Polarized cells were obtained as described in Meen et. al. (29). GEnC were cultured for 5 
days at the non-permissive temperature, and then seeded on semipermeable filters; Costar 
Transwell clear polyester membrane inserts with a pore size of 0.4 µ𝑚 (Sigma-Aldrich) in 12-
well plates. The cells were seeded at a density of 1 × 105 cells/cm2 with 1.5 ml of culture 
medium in the basolateral compartment and 0.5 ml in the apical compartment and cultured 
for several days to obtain a confluent monolayer and allow the cells to polarize. The medium 
was changed every second day until the start of the experiment, when a tight monolayer had 




conditions in the form of hyperglycemia (25 mM glucose) and / or 0.5 ng/ml IL-1β at 33oC 
and 5% CO2 for 24 hours, and compared to control cells cultured in 5 mM glucose.  
Cytotoxicity assay 
The possible cytotoxic effect of exposure to IL-1β and hyperglycemia was investigated by 
measurement of lactate dehydrogenase (LDH) activity released from damaged cells, using 
the Cytotoxicity Detection Kit (11 644 793 001, Roche) according to the manufacturer’s 
instructions. In brief, conditioned media from cells cultured under the different conditions 
was harvested; assay reagent was added and incubated at 20°C for up to 30 min before 
recording the absorbance at 490 nm. Conditioned media from Triton X-100 treated cells 
were included as positive control, and non-conditioned medium was included as negative 
control. % of maximum cytotoxicity (positive control) was calculated for each sample. 
ELISA-assays 
Conditioned medium was collected and centrifuged to remove cell debris, and shedded 
syndecan-4 and soluble intracellular adhesion molecule-1 (sICAM-1) were detected 
according to the manufacturer’s instructions using the Human Syndecan-4 Assay Kit 
(JP27188, IBL) and Human ICAM-1/CD54 Duoset-1 (DY720-05, R&D). All standards were 
within the limits of detection and inter- and intra-assay coefficient of variation (CV) was < 
10%. 
Gene expression analysis 
Total RNA was isolated from cultured GEnC using the E.Z.N.A. Total RNA kit 1 (R6834-02, 
Omega Bio-Tek) according to the manufacturer’s instructions. RNA quantity measurements 




stored at -20°C until further analysis. A quantity of 250 ng RNA was reversely transcribed in a 
total volume of 20 μl using the “High capacity RNA-to-cDNA kit” (4387406, Applied 
Biosystems). Quantitative Real-time PCR (qRT-PCR) was performed on a CFX96 Real-Time 
System c1000 Touch (BIO-RAD) using TaqMan Gene Expression Master Mix (4369016, 
Applied Biosystems) and predesigned TaqMan Gene Expression Assays as listed in Table 1. 
60S ribosomal protein L30 (RPL30) or beta actin (ACTB) was used as endogenous control. The 
cycle threshold (Ct) cutoff value was set to 40 cycles, and the relative mRNA level for each 
transcript was calculated by the ∆∆Ct method (30). Briefly, the Ct values for each gene was 
normalized against the Ct values of the reference gene (= ∆Ct). For comparison of gene 
expression in treated versus control cells, ∆∆Ct was calculated as ∆Ct in treated cells 
subtracted the ∆Ct for control cells. The fold change in mRNA expression was calculated as 2-
∆∆Ct.  
Gene knockdown 
The expression of human MMP9 was reduced using siRNA (sc-29400, Santa Cruz) or the 
silencer negative control siRNA (scramble, AM4635, Ambion) at 0.02 μM. ciGEnCells were 
reversly transfected with Lipofectamine RNAiMAX transfection reagent (13778030, Thermo 
Fisher Sceintific) in Opti-MEM (Invitrogen) at a cell density of 200 000 cells per ml (25 000 
cells / cm2), allowed to adhere and incubated for 20 hours. Then, the transfection medium 
was replaced with MCDB growth medium and experiment initiated. The silencing efficiency 
was quantified by qRT-PCR.  
Statistical analysis 
The data were analyzed using Graph Pad Prism 5.03. Data are presented as mean ± SEM of 




using the Student’s paired t-test, One-way ANOVA or Two-way ANOVA as appropriate. 
Differences of p<0.05 were considered significant.  
 
Results 
Polarized ciGEnCells were subjected to experimental diabetic conditions in the form of 
hyperglycemia (25 mM glucose) and / or 0.5 ng/ml IL-1β for 24 hours, and compared to 
control cells cultured under normoglycemic conditions of 5 mM glucose. Both morphological 
inspection and von Willebrand Factor (vWF) expression indicated that the cells retained the 
characteristics of primary endothelial cells (Fig 1A and B). Cytotoxicity determined by LDH-
leakage showed no reduced viability as a result of the treatments (Fig 1C ). 
Increased expression of ICAM-1 and shedding of ICAM-1 from the endothelial cell surface 
are signs of endothelial cell activation or dysfunction. We observed a constitutive shedding 
of sICAM-1 to the apical side of the cells, while the levels retrieved at the basolateral side 
were comparably very low. Upon IL-1β stimulation, the levels of sICAM-1 were increased 1.8 
fold at the apical side. The basolateral levels were increased 20 fold, but were still at very 
low levels compared to the apical levels. Hyperglycemia on the other hand, had no effect on 
the levels of sICAM-1 (Fig 2A).  Also; ICAM-1 gene expression was increased 2.7 fold by IL-1β-
stimulation while unaffected by hyperglycemia (Fig 2B). 
We found that ciGEnCells express all four syndecans, but syndecan-4 was more highly 
expressed than the other syndecans (Fig 2C). Syndecan -4 expression was significantly 
increased by IL-1β but not glucose (Fig 2D). The levels of shedded syndecan-1 were below 
the limit of detection, and we lacked satisfying tools for detection of soluble syndecan-2 and 




cells.  This was increased 1.6 fold to the apical side and 1.2 fold to the basolateral side as a 
response to IL-1β stimulation (Fig 2E), but remained unaffected by hyperglycemia. In line 
with this, gene expression was unaffected by hyperglycemia, but increased 1.6 fold by IL-1β-
stimulation (Fig 2F). 
Several sheddases are candidates for the regulation of syndecan-4 shedding (17). The 
relative gene expression of these sheddases (MMP2, MMP9, ADAM17, a disintegrin and 
metalloproteinase (ADAMST)1, ADAMST 4) and some of their inhibitors (tissue inhibitor of 
metalloproteinases (TIMP)-1 and TIMP-2) was determined (Fig 3). Among these targets, only 
MMP9 was increased by IL-1β (Fig 3). Hyperglycemia did not affect gene expression of any of 
these targets. This observation led us to hypothesize that MMP9 is involved in the 
inflammation-driven increase in syndecan-4 shedding in these cells.  
To investigate further the possible role of MMP9 in syndecan-4 shedding, we made use of 
siRNA gene silencing (Fig 4A). Gene silencing reduced MMP9 gene expression by 84 % in 
unstimulated cells and with 65 % in IL-1β stimulated cells. This resulted in a 47 % reduction 
in syndecan-4 shedding in unstimulated cells and a 51 % reduction in stimulated cells (Fig 4B). 
SDC4 gene expression was not affected by MMP9 knockdown (Fig 4C). Comparison of 
siMMP9 to scrambled RNA gave similar results, indicating no effect of siRNA transfection per 
se. In comparison, soluble levels and gene expression of s-ICAM-1 was not reduced by the 







In this study, in human glomerular endothelial cells we found that shedding of both 
syndecan-4 and ICAM-1 was increased by the pro-inflammatory cytokine IL-1β, but not by 
hyperglycemia. Furthermore, MMP9 was involved in shedding of syndecan-4, but not ICAM-
1. The main results illustrating that IL-1β but not hyperglycemia increase the shedding of 
syndecan-4 from GEnC in an MMP9-dependent manner are illustrated in Fig. 5. 
These results are comparable to the findings of Ramnath R et. al. They showed that 
treatment with the pro-inflammatory cytokine tissue necrosis factor (TNF)α induced MMP9-
mediated shedding of syndecan-4 in the same cell type as in our study. Importantly, they 
demonstrated that syndecan-4 shedding resulted in increased permeability of ciGEnC 
monolayers (27). This translates to a role of syndecan-4 in glycocalyx integrity.  
The components of the glomerular filtration barrier are the specialized fenestrated 
glomerular endothelial cells covered with its glycocalyx, the glomerular basement 
membrane, and the podocytes with their slits. The endothelial glycocalyx has emerged as an 
important component of the renal filtration barrier. Structural alterations and shedding of 
glycocalyx components is seen in diabetic nephropathy (31, 32), and disruption of the 
glycocalyx leads to proteinuria in various experimental in vivo studies (33, 34). The 
syndecans are important constituent of the glycocalyx, and in line with other publications we 
found that syndecan-4 is highly expressed by GEnC and an important component of the 
glycocalyx (27). We hypothesized that hyperglycemia and IL-1β contribute to impaired renal 
filtration in diabetes trough increasing the shedding of syndecan-4 from the surface of 




Increased expression of ICAM-1 and release of sICAM-1 from the endothelial cell surface are 
signs of endothelial activation or dysfunction. In our hands, hyperglycemia had no effect on 
ICAM-1 gene expression or sICAM-1 levels in GEnC. Furthermore, we found no effect of 
hyperglycemia on syndecan-4 shedding or gene expression. This indicates that 
hyperglycemic conditions are tolerated well by these cells, not resulting in cellular 
dysfunction or stress.  These observations are in contrast to Singh A et.al., who 
demonstrated decreased synthesis of glycosaminoglycans (the sugar side chains of 
proteoglycans including syndecans) and increased permeability as a result of high glucose 
treatment in GEnC (35). However, the discrepancy between these two studies could be 
explained by the different experimental conditions used. Our exposure to hyperglycemia 
was short term (24 hours), while Sing et al stimulated the cells for 2-14 days.  We chose to 
perform a more short term exposure to high glucose, in line with what is practically feasible 
and as a commonly used time point.  
In clear contrast to the lack of effects seen after hyperglycemic treatment, we found that the 
pro-inflammatory cytokine IL-1β lead to activation of the endothelial cells. Both gene 
expression and the constitutive release of ICAM-1 from the apical surface were increased as 
a response to this treatment. This was accompanied by an increase in apical shedding and 
gene expression of the glycocalyx component syndecan-4.  
These results suggest that the detrimental effects of the diabetic condition on glomerular 
endothelium are not caused by direct effects of glucose on the endothelium, but rather 
mediated trough secondary downstream effects of hyperglycemia or other aspects of the 
diabetic state. Several mechanisms are proposed for how glucose levels through altered flux 




advanced glycated end products (AGE)-formation and receptor for AGE (RAGE)-binding, 
activation of protein kinese C (PKC) and increased O-linked N-acetylglucosamine (O-GlcNAc) 
signaling (36). Accordingly, increased levels of proinflammatory cytokines including IL-1β are 
seen in hyperglycemia and diabetes (11, 12). Endothelial cells respond to several cytokines 
released systemically, including the classical proinflammatory IL-1 cytokines. IL-1β signals via 
IL-1 Receptor-1. This results in activation of transcription factors including nuclear factor κB 
(NFκB), inducing the mRNA expression of a series of genes to exert biological effects (37). 
The activation of the IL-1 pathway is linked to atherogenesis and CVD in diabetes (11). In 
recent years, new pathways involved in the development and progression of diabetic kidney 
disease have been elucidated; and accumulated data have emphasized the critical role of 
inflammation in the pathogenesis of diabetic nephropathy, triggered by factors such as 
increased intraglomerular pressure and hyperfiltration (38).  
We investigated the regulation of IL-1β-induced syndecan-4 shedding in the glomerular 
endothelial cells. According to the literature, there are several candidate sheddases of 
syndecan-4 (17), including MMP2, MMP9, ADAM17, ADAMTS1, ADAMTS4 and the inhibitors 
TIMP-1 and TIMP-2. However, only expression of MMP9 was increased by IL-1β. Silencing 
the MMP9 gene we showed that syndecan-4 shedding was regulated by MMP-9. ICAM-1 
release from the cell surface, however, was not affected in the MMP9 knockdown, indicating 
that the shedding of this component is differently regulated.  
A major part of the functionality of the syndecans is mediated by their glycosaminoglycan 
side chains interacting with different partner molecules. The functional consequences of 
shedding of glycocalyx components are under intensive study. Increased shedding could 




degradation and shedding is dysregulated. Alternatively, shedding could be a protective 
mechanism, by reducing intracellular signaling and intracellular events, to protect partner 
molecules from degradation or to present them to other cells, to create chemotactic 
gradients, or to clear the components in the liver. Importantly, it is reasonable to assume 
that shedded syndecans and syndecans present at the cell surface have very different 
functions.  
Strengths and limitations 
Some limitations of this study warrant discussion. In this study, we chose to study the effects 
of short-term hyperglycemia, although long term exposure is also of obvious interest in 
diabetes. The disorder of glucose levels in diabetes has two main components: long-term 
chronic hyperglycemia and acute glycemic fluctuations between high and low values. Acute 
hyperglycemia has been associated with increased endothelial dysfunction and permeability 
(8). However, the impacts of chronic hyperglycemia are more extensively studied (39, 40). 
As a simplified in vitro study, this model do not reflect all parameters present in vivo, 
including all components of the blood, sheer stress etc. However the simplified in vitro 
approach has advantages when studying the contribution of individual components. Another 
strength of the study is the more in vivo relevant system of polarized cells obtained by 
culturing the on semipermeable filters.  
Perspectives 
The glomerular endothelium is emerging as a key player in diabetic nephropathy. IL-1β 
increases the shedding of syndecan-4 from these cells in an MMP9-dependent manner. This 




conditions. The glycocalyx is present at the apical surface of all endothelial cells, and damage 
of the glycocalyx has been implicated in several diseases. Thus, the implications of this work 
are not limited to glomerular endothelium, but extend to vascular function and disease 
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Table 1 – TaqMan gene expression assays used in qRT-PCR analysis 
Gene Protein Assay ID 
RPL30 60S ribosomal protein L30 Hs00265497_m1 
ACTB Beta actin Hs99999903_m1 
VWF Von Willebrand Factor Hs01109446_m1 
MMP9 Matrix metalloproteinase-9 Hs00234579_m1 
MMP2 Matrix metalloproteinase-2 Hs01548727_m1 
TIMP1 Tissue inhibitor of metalloproteinases-1 Hs00171558_m1 
TIMP2 Tissue inhibitor of metalloproteinases-2 Hs00234278_m1 
ADAM17 ADAM-17 Hs01041915_m1 
ADAMTS1 ADAMTS1 Hs00199608_m1 
ADAMTS4 ADAMTS4 Hs00192708_m1 
SDC1 Syndecan-1 Hs00896423_m1 
SDC2 Syndecan-2 Hs00299807_m1 
SDC3 Syndecan-3 Hs00206320_m1 
SDC4 Syndecan-4 Hs00161617_m1 







Fig 1. (A) Normal endothelial cobblestone morphology of a confluent layer of ciGEnCells at 
37oC, both control cells (Ctr) and IL-1β stimulated cells (IL-1β).. (B) Gene expression of the 
endothelial marker vWF in control cells at 37oC, expressed as ΔCt values (Ct of target gene – 
Ct of reference gene), n=4. (C) Cytotoxicity of IL-1β, hyperglycemia or the combination when 
exposed to ciGEnCells at 37oC  for 24 hours and compared to untreated control cells (Ctr), 
n=6. Only statistical significant differences related to the ctr are marked in the figures. * 
p<0.05, **p<0.01, ***p<0.001 
Fig 2. Effect of hyperglycemia and IL-1β on ICAM-1 and syndecan shedding and gene 
expression (A) Soluble ICAM-1 levels detected in the apical and basolateral compartements, 
compared to the apical control, n=8. (B) Gene expression of ICAM-1 expressed as fold 
change and related to the untreated Ctr, n=6. (C) Comparison of gene expression levels of 
the syndecans, presented as ΔCt values (Ct of target gene – Ct of reference gene). Note that 
the lower the Ct value, the higher gene expression, n=3. (D) Effect of experimental diabetic 
conditions on syndecan gene expression levels, expressed as fold change related to the 
untreated control, n=3. (E) Levels of shedded syndecan-4 in the apical and basolateral 
compartments, compared to the apical control, n=7. (F) Gene expression of SDC4 expressed 
as fold change and related to the untreated Ctr, n=6. Only statistical significant differences 
related to the ctr are marked in the figures. * p<0.05, **p<0.01, ***p<0.001 
Fig 3. Effect of hyperglycemia and IL-1β on sheddase gene expression. Effect of IL-1β, 25 
mM of glucose or the combination on gene expression of sheddases, expressed as fold 




related to the ctr are marked in the figures. * p<0.05, **p<0.01, ***p<0.001, and each target 
is evaluated independently.  
Fig. 4. Effects of MMP-9 gene silencing on syndecan-4 and ICAM-1 shedding and gene 
expression. (A) MMP9 expression in MMP9 knockdown (siMMP9) compared to control (Ctr) 
both in the absence and presence of IL-1β stimulation, n=7 .(B, C) Levels of shedded 
syndecan-4, n=6 (B) and SDC4 gene expression, n=3 (C) in unstimulated and IL-1β stimulated 
MMP9 knockdown cells compared to unstimulated and IL-1β stimulated control cells. (D, E) 
Levels of soluble ICAM-1 (D) and ICAM-1 gene expression (E) in unstimulated and IL-1β 
stimulated MMP9 knockdown cells compared to unstimulated and IL-1β stimulated control 
cells, n=3. Gene expressions were presented as fold change relative to untreated control 
(Ctr). It is indicated whether or not siMMP9 data are significantly different from ctr, and 
whether or not  siMMP9 + IL1β data are significantly different from IL-1β. ns p>0.05, * 
p<0.05, **p<0.01, ***p<0.001. 
Fig 5. Inflammation but not hyperglycemia increase endothelial syndecan-4 shedding in an 
MMP9-dependent manner. (A) In control cells, syndecan-4 is presented mainly at the apical 
surface of the endothelium with a constitutive but low degree of shedding. (B) 
Hyperglycemia alone did not affect syndecan-4 shedding from the cell surface. (C) In contrast, 
the pro-inflammatory cytokine IL-1β increased gene expression of syndecan-4 and MMP-9, 
increasing the MMP-9 mediated shedding of syndecan-4 and levels of soluble syndecan-4. 
AP: apical side (vessel lumen), BL: basolateral side. 
 
